Novartis Receives FDA Approval for Cosentyx in Polymyalgia Rheumatica
Novartis announced FDA approval of Cosentyx (secukinumab) for polymyalgia rheumatica in adults. The 150-mg dose was approved based on Phase III trial results showing 40.5% sustained remission vs. 20.5% for placebo. This is the 11th US approval for Cosentyx, which also has EU approval for this indication.
How this was made

The 30-second read
Why it matters
The FDA approval provides a new treatment option for steroid-inadequate or steroid-taper-intolerant PMR patients, supported by Phase III REPLENISH efficacy at Week 52 and a defined safety profile.
Market read
A new FDA-labeled indication for Cosentyx in PMR is a direct, company-specific regulatory catalyst with trial-backed efficacy and safety rates.
What to watch
The article highlights higher hypersensitivity and urinary tract infection rates versus placebo; traders may watch for how clinicians weigh these risks versus steroid-sparing benefits and how quickly PMR specialists adopt the 150 mg regimen.
Background
Polymyalgia rheumatica (PMR) primarily affects adults over 50 and is commonly treated with corticosteroids, which carry long-term complication risks.
Ticker impact
Novartis announced FDA approval of Cosentyx for adults with polymyalgia rheumatica, expanding Cosentyx to an 11th US indication.
Likely positive bias as the market prices in incremental revenue opportunity from a new FDA-approved indication.
The article is a first-report FDA approval with Phase III efficacy and specific safety rates, which typically drives near-term sentiment for the issuer.
Market effects
Reinforces IL-17 biologics positioning in inflammatory rheumatology and may increase competitive attention on other biologic candidates for PMR.
US label expansion can shift prescribing patterns in the US ahead of ongoing reviews in other markets (e.g., Japan).
Adds to the global uptake narrative for secukinumab as regulators continue reviewing additional indications beyond the EU.
Counterpoint
Approval does not guarantee rapid uptake; real-world prescribing may be constrained by safety tolerability, steroid-reduction practicality, and payer coverage decisions.
Key entities
- companyNovartis
US-listed issuer announcing FDA approval for Cosentyx in PMR.
- drugCosentyx (secukinumab)
IL-17 biologic approved for adults with PMR with inadequate response to corticosteroids or inability to reduce steroid treatment.
- regulatorFDA
Regulatory body granting the US approval based on REPLENISH trial data.



